

# JosÃ© HernÃ¡ndez-RodrÃ­guez

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3524089/publications.pdf>

Version: 2024-02-01

135  
papers

5,997  
citations

57758

44  
h-index

76900

74  
g-index

143  
all docs

143  
docs citations

143  
times ranked

4143  
citing authors

#	ARTICLE	IF	CITATIONS
1	A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. <i>Arthritis and Rheumatism</i> , 2002, 46, 1309-1318.	6.7	480
2	Large vessel involvement in biopsy-proven giant cell arteritis: prospective study in 40 newly diagnosed patients using CT angiography. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1170-1176.	0.9	300
3	Tissue production of pro-inflammatory cytokines (IL-1, TNF and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. <i>British Journal of Rheumatology</i> , 2003, 43, 294-301.	2.3	237
4	Diagnosis and classification of polyarteritis nodosa. <i>Journal of Autoimmunity</i> , 2014, 48-49, 84-89.	6.5	189
5	Development of aortic aneurysm/dilatation during the followup of patients with giant cell arteritis: A cross-sectional screening of fifty-four prospectively followed patients. <i>Arthritis and Rheumatism</i> , 2008, 59, 422-430.	6.7	174
6	Elevated Production of Interleukin-6 Is Associated With a Lower Incidence of Disease-Related Ischemic Events in Patients With Giant-Cell Arteritis. <i>Circulation</i> , 2003, 107, 2428-2434.	1.6	169
7	Relapses in Patients With Giant Cell Arteritis. <i>Medicine (United States)</i> , 2014, 93, 194-201.	1.0	158
8	Positron emission tomography assessment of large vessel inflammation in patients with newly diagnosed, biopsy-proven giant cell arteritis: a prospective, case-control study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1388-1392.	0.9	148
9	A Large-Scale Genetic Analysis Reveals a Strong Contribution of the HLA Class II Region to Giant Cell Arteritis Susceptibility. <i>American Journal of Human Genetics</i> , 2015, 96, 565-580.	6.2	144
10	Cell adhesion molecules in the development of inflammatory infiltrates in giant cell arteritis: Inflammation-induced angiogenesis as the preferential site of leukocyte-endothelial cell interactions. <i>Arthritis and Rheumatism</i> , 2000, 43, 184-194.	6.7	128
11	A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis. <i>Arthritis and Rheumatism</i> , 2002, 47, 29-35.	6.7	127
12	Small-vessel vasculitis surrounding a spared temporal artery: Clinical and pathologic findings in a series of twenty-eight patients. <i>Arthritis and Rheumatism</i> , 2001, 44, 1387-1395.	6.7	105
13	Treatment of Polymyalgia Rheumatica. <i>Archives of Internal Medicine</i> , 2009, 169, 1839.	3.8	104
14	Somatic NLRP3 mosaicism in Muckle-Wells syndrome. A genetic mechanism shared by different phenotypes of cryopyrin-associated periodic syndromes. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 603-610.	0.9	104
15	Prospective long term follow-up of a cohort of patients with giant cell arteritis screened for aortic structural damage (aneurysm or dilatation). <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1826-1832.	0.9	103
16	Tissue and Serum Angiogenic Activity Is Associated With Low Prevalence of Ischemic Complications in Patients With Giant-Cell Arteritis. <i>Circulation</i> , 2002, 106, 1664-1671.	1.6	99
17	Virologic, Clinical, and Immune Response Outcomes of Patients With Hepatitis C Virus-Associated Cryoglobulinemia Treated With Direct-Acting Antivirals. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 575-583.e1.	4.4	99
18	Tissue and serum markers of inflammation during the follow-up of patients with giant-cell arteritis—a prospective longitudinal study. <i>Rheumatology</i> , 2011, 50, 2061-2070.	1.9	97

#	ARTICLE	IF	CITATIONS
19	Increased IL-17A expression in temporal artery lesions is a predictor of sustained response to glucocorticoid treatment in patients with giant-cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1481-1487.	0.9	96
20	Antineutrophil Cytoplasmic Antibody-Associated Vasculitides and Respiratory Disease. <i>Chest</i> , 2009, 136, 1101-1111.	0.8	92
21	Blocking interferon $\gamma$ reduces expression of chemokines CXCL9, CXCL10 and CXCL11 and decreases macrophage infiltration in ex vivo cultured arteries from patients with giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1177-1186.	0.9	89
22	Early recruitment of phagocytes contributes to the vascular inflammation of giant cell arteritis. <i>Journal of Pathology</i> , 2004, 204, 311-316.	4.5	88
23	Effect of Glucocorticoid Treatment on Computed Tomography Angiography Detected Large-Vessel Inflammation in Giant-Cell Arteritis. A Prospective, Longitudinal Study. <i>Medicine (United States)</i> , 2015, 94, e486.	1.0	78
24	A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. <i>American Journal of Human Genetics</i> , 2017, 100, 64-74.	6.2	78
25	Gelatinase expression and proteolytic activity in giant-cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1429-1435.	0.9	76
26	Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor $\alpha$ and $\gamma$ ) in giant cell arteritis. <i>Research</i> , 2010, 62, 835-841.	3.4	75
27	Long-Term Outcomes of Patients With HCV-Associated Cryoglobulinemic Vasculitis After Virologic Cure. <i>Gastroenterology</i> , 2018, 155, 311-315.e6.	1.3	73
28	Imatinib mesylate inhibits in vitro and ex vivo biological responses related to vascular occlusion in giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 1581-1588.	0.9	71
29	Updating single-organ vasculitis. <i>Current Opinion in Rheumatology</i> , 2012, 24, 38-45.	4.3	69
30	Interferon- $\gamma$ may exacerbate cryoglobulinemia-related ischemic manifestations: An adverse effect potentially related to its anti-angiogenic activity. <i>Arthritis and Rheumatism</i> , 1999, 42, 1051-1055.	6.7	68
31	Changes in biomarkers after therapeutic intervention in temporal arteries cultured in Matrigel: a new model for preclinical studies in giant-cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 616-623.	0.9	68
32	Endothelin-1 promotes vascular smooth muscle cell migration across the artery wall: a mechanism contributing to vascular remodelling and intimal hyperplasia in giant-cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1624-1634.	0.9	67
33	Association between increased CCL2 (MCP-1) expression in lesions and persistence of disease activity in giant-cell arteritis*. <i>Rheumatology</i> , 2006, 45, 1356-1363.	1.9	64
34	Central Nervous System Vasculitis: Still More Questions than Answers. <i>Current Neuropharmacology</i> , 2011, 9, 437-448.	2.9	64
35	Clinical and genetic characterization of the autoinflammatory diseases diagnosed in an adult reference center. <i>Autoimmunity Reviews</i> , 2016, 15, 9-15.	5.8	62
36	Increased expression of the endothelin system in arterial lesions from patients with giant-cell arteritis: association between elevated plasma endothelin levels and the development of ischaemic events. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 434-442.	0.9	59

#	ARTICLE	IF	CITATIONS
37	DNA demethylation of inflammasome-associated genes is enhanced in patients with cryopyrin-associated periodic syndromes. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 202-211.e6.	2.9	57
38	Surgical interventions and local therapy for Wegener's granulomatosis. <i>Current Opinion in Rheumatology</i> , 2010, 22, 29-36.	4.3	55
39	Description and Validation of Histological Patterns and Proposal of a Dynamic Model of Inflammatory Infiltration in Giant-cell Arteritis. <i>Medicine (United States)</i> , 2016, 95, e2368.	1.0	55
40	Circulating soluble adhesion molecules in patients with giant cell arteritis. Correlation between soluble intercellular adhesion molecule-1 (sICAM-1) concentrations and disease activity. <i>Annals of the Rheumatic Diseases</i> , 1999, 58, 189-192.	0.9	53
41	Single-organ vasculitis. <i>Current Opinion in Rheumatology</i> , 2008, 20, 40-46.	4.3	52
42	Analysis of the common genetic component of large-vessel vasculitides through a meta-ImmunoChip strategy. <i>Scientific Reports</i> , 2017, 7, 43953.	3.3	52
43	Identification of the <i>PTPN22</i> functional variant R620W as susceptibility genetic factor for giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1882-1886.	0.9	51
44	Treatment with statins does not exhibit a clinically relevant corticosteroid-sparing effect in patients with giant cell arteritis. <i>Arthritis and Rheumatism</i> , 2004, 51, 674-678.	6.7	48
45	Current Therapeutic Options for the Main Monogenic Autoinflammatory Diseases and PFAPA Syndrome: Evidence-Based Approach and Proposal of a Practical Guide. <i>Frontiers in Immunology</i> , 2020, 11, 865.	4.8	48
46	Trabecular bone score improves fracture risk assessment in glucocorticoid-induced osteoporosis. <i>Rheumatology</i> , 2020, 59, 1574-1580.	1.9	47
47	The spectrum of vascular involvement in giant cell arteritis: clinical consequences of detrimental vascular remodelling at different sites. <i>Apmis</i> , 2009, 117, 10-20.	2.0	44
48	Gynecologic Vasculitis. <i>Medicine (United States)</i> , 2009, 88, 169-181.	1.0	44
49	Nasoseptal Perforation: from Etiology to Treatment. <i>Current Allergy and Asthma Reports</i> , 2018, 18, 5.	5.3	44
50	Endothelial cells, antineutrophil cytoplasmic antibodies, and cytokines in the pathogenesis of systemic vasculitis. <i>Current Rheumatology Reports</i> , 2004, 6, 184-194.	4.7	43
51	Testicular Vasculitis. <i>Medicine (United States)</i> , 2012, 91, 75-85.	1.0	42
52	Disease Phenotype and Outcome Depending on the Age at Disease Onset in Patients Carrying the R92Q Low-Penetrance Variant in <i>TNFRSF1A</i> Gene. <i>Frontiers in Immunology</i> , 2017, 8, 299.	4.8	41
53	Development of Ischemic Complications in Patients With Giant Cell Arteritis Presenting With Apparently Isolated Polymyalgia Rheumatica. <i>Medicine (United States)</i> , 2007, 86, 233-241.	1.0	38
54	Association of <i>NOS2</i> and potential effect of <i>VEGF</i> , <i>IL6</i> , <i>CCL2</i> and <i>IL1RN</i> polymorphisms and haplotypes on susceptibility to GCA—a simultaneous study of 130 potentially functional SNPs in 14 candidate genes. <i>Rheumatology</i> , 2012, 51, 841-851.	1.9	38

#	ARTICLE	IF	CITATIONS
55	Influence of the IL17A locus in giant cell arteritis susceptibility. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1742-1745.	0.9	36
56	Domains of health-related quality of life important to patients with giant cell arteritis. <i>Arthritis and Rheumatism</i> , 2003, 49, 819-825.	6.7	35
57	Vasculitis Involving the Breast. <i>Medicine (United States)</i> , 2008, 87, 61-69.	1.0	35
58	Single-Organ Gallbladder Vasculitis. <i>Medicine (United States)</i> , 2014, 93, 405-413.	1.0	35
59	Serum osteopontin: a biomarker of disease activity and predictor of relapsing course in patients with giant cell arteritis. Potential clinical usefulness in tocilizumab-treated patients. <i>RMD Open</i> , 2017, 3, e000570.	3.8	33
60	Expression and Function of IL12/23 Related Cytokine Subunits (p35, p40, and p19) in Giant-Cell Arteritis Lesions: Contribution of p40 to Th1- and Th17-Mediated Inflammatory Pathways. <i>Frontiers in Immunology</i> , 2018, 9, 809.	4.8	33
61	Rituximab treatment for IgA vasculitis: A systematic review. <i>Autoimmunity Reviews</i> , 2020, 19, 102490.	5.8	32
62	The Expanding Role of Imaging in Systemic Vasculitis. <i>Rheumatic Disease Clinics of North America</i> , 2016, 42, 733-751.	1.9	30
63	Biological treatments in giant cell arteritis & Takayasu arteritis. <i>European Journal of Internal Medicine</i> , 2018, 50, 12-19.	2.2	30
64	Dermatologic and Dermatopathologic Features of Monogenic Autoinflammatory Diseases. <i>Frontiers in Immunology</i> , 2019, 10, 2448.	4.8	29
65	Treatment with angiotensin II receptor blockers is associated with prolonged relapse-free survival, lower relapse rate, and corticosteroid-sparing effect in patients with giant cell arteritis. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 772-777.	3.4	28
66	Five Clinical Conundrums in the Management of Giant Cell Arteritis. <i>Rheumatic Disease Clinics of North America</i> , 2007, 33, 819-834.	1.9	26
67	Efficacy and safety of TNF- $\alpha$ antagonists and tocilizumab in Takayasu arteritis: multicentre retrospective study of 209 patients. <i>Rheumatology</i> , 2022, 61, 1376-1384.	1.9	26
68	Characterization of isolated retinal vasculitis. Analysis of a cohort from a single center and literature review. <i>Autoimmunity Reviews</i> , 2017, 16, 237-243.	5.8	25
69	Clinical Features at Onset and Genetic Characterization of Pediatric and Adult Patients with TNF- $\alpha$ Receptor-Associated Periodic Syndrome (TRAPS): A Series of 80 Cases from the AIDA Network. <i>Mediators of Inflammation</i> , 2020, 2020, 1-12.	3.0	24
70	Evidence of association of the NLRP1 gene with giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 628-630.	0.9	23
71	Tocilizumab: from the rheumatology practice to the fight against COVID-19, a virus infection with multiple faces. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 717-723.	3.1	20
72	Methylome and transcriptome profiling of giant cell arteritis monocytes reveals novel pathways involved in disease pathogenesis and molecular response to glucocorticoids. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1290-1300.	0.9	20

#	ARTICLE	IF	CITATIONS
73	Pneumocystis jirovecii pneumonia prophylaxis in immunocompromised patients with systemic autoimmune diseases. <i>Medicina Clínica</i> , 2019, 152, 502-507.	0.6	19
74	Sustained spontaneous clinical remission in giant cell arteritis: Report of two cases with long-term followup. <i>Arthritis and Rheumatism</i> , 2006, 55, 160-162.	6.7	17
75	Successful treatment of severe COVID-19 with subcutaneous Anakinra as a sole treatment. <i>Rheumatology</i> , 2020, 59, 2171-2173.	1.9	17
76	A Candidate Gene Approach Identifies an IL33 Genetic Variant as a Novel Genetic Risk Factor for GCA. <i>PLoS ONE</i> , 2014, 9, e113476.	2.5	17
77	Epidemiological study of primary systemic vasculitides among adults in southern Spain and review of the main epidemiological studies. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S-11-8.	0.8	16
78	Advances in the Diagnosis of Large Vessel Vasculitis. <i>Rheumatic Disease Clinics of North America</i> , 2015, 41, 125-140.	1.9	15
79	New Potential Weapons for Refractory Scleritis in the Era of Targeted Therapy. <i>Mediators of Inflammation</i> , 2020, 2020, 1-6.	3.0	15
80	CHARACTERIZING COVID-19-RELATED RETINAL VASCULAR OCCLUSIONS. <i>Retina</i> , 2022, 42, 465-475.	1.7	14
81	Response to mepolizumab according to disease manifestations in patients with eosinophilic granulomatosis with polyangiitis. <i>European Journal of Internal Medicine</i> , 2022, 95, 61-66.	2.2	12
82	Development and Implementation of the AIDA International Registry for Patients With Still's Disease. <i>Frontiers in Medicine</i> , 2022, 9, 878797.	2.6	9
83	Renal tubular acidosis type IV as a complication of lupus nephritis. <i>Lupus</i> , 2016, 25, 307-309.	1.6	8
84	Enfermedades autoinflamatorias monogénicas: conceptos generales y presentación en pacientes adultos. <i>Medicina Clínica</i> , 2018, 150, 67-74.	0.6	8
85	Prevalence of cardiovascular risk factors, the use of statins and of aspirin in Takayasu Arteritis. <i>Scientific Reports</i> , 2021, 11, 14404.	3.3	8
86	Spectrum of Disease Manifestations in Patients with Selective Immunoglobulin E Deficiency. <i>Journal of Clinical Medicine</i> , 2021, 10, 4160.	2.4	8
87	Low serum osteocalcin levels are associated with diabetes mellitus in glucocorticoid treated patients. <i>Osteoporosis International</i> , 2022, 33, 745-750.	3.1	8
88	Limited Utility of Rapamycin in Severe, Refractory Wegener's Granulomatosis. <i>Journal of Rheumatology</i> , 2009, 36, 116-119.	2.0	7
89	Treatment of Large Vessel Vasculitis. <i>Current Immunology Reviews</i> , 2011, 7, 435-442.	1.2	7
90	ANCA-associated vasculitic neuropathy during treatment with ipilimumab. <i>Rheumatology</i> , 2020, 59, 251-252.	1.9	7

#	ARTICLE	IF	CITATIONS
91	Role of Colchicine Treatment in Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS): Real-Life Data from the AIDA Network. <i>Mediators of Inflammation</i> , 2020, 2020, 1-6.	3.0	7
92	Editorial: Autoinflammatory Diseases: From Genes to Bedside. <i>Frontiers in Immunology</i> , 2020, 11, 1177.	4.8	7
93	Identification of a shared genetic risk locus for Kawasaki disease and immunoglobulin A vasculitis by a cross-phenotype meta-analysis. <i>Rheumatology</i> , 2022, 61, 1204-1210.	1.9	7
94	New therapeutic targets in giant-cell arteritis. Considerations based on the current pathogenic model and the availability of new therapeutic agents. <i>Clinical and Experimental Rheumatology</i> , 2008, 26, S141-50.	0.8	6
95	Vertebral fracture risk in glucocorticoid-induced osteoporosis: the role of hypogonadism and corticosteroid boluses. <i>RMD Open</i> , 2020, 6, e001355.	3.8	5
96	Simultaneous presentation of granulomatosis with polyangiitis (GPA) and immunoglobulin G4-related disease (IgG4-RD). Leaving an open question: widening the spectrum of a single disease or real overlap?. <i>Modern Rheumatology Case Reports</i> , 2021, 5, 108-112.	0.7	4
97	Drug survival of anakinra and canakinumab in monogenic autoinflammatory diseases: observational study from the International AIDA Registry. <i>Rheumatology</i> , 2021, 60, 5705-5712.	1.9	4
98	Small-vessel vasculitis with prominent IgG4 positive plasma cell infiltrates as potential part of the spectrum of IgG4-related disease: a case report. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S-138-41.	0.8	4
99	Effectiveness of TNF- $\alpha$ blockade in the treatment of refractory non-infectious scleritis: a multicentre study. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 1138-1144.	0.8	4
100	Why lupus patients discontinue antimalarials in real life: A 50 years-experience from a reference centre. <i>Lupus</i> , 2022, 31, 1344-1354.	1.6	4
101	Evaluation of Aortic Inflammation Using Computed Tomographic Angiography: Vasculitis, Atherosclerosis, or Both. <i>Journal of the American Geriatrics Society</i> , 2015, 63, 415-416.	2.6	3
102	A TNFSF13B functional variant is not involved in systemic sclerosis and giant cell arteritis susceptibility. <i>PLoS ONE</i> , 2018, 13, e0209343.	2.5	3
103	Anakinra-induced psoriasis in a patient with Schnitzler's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 191-192.	0.8	3
104	Small-vessel vasculitis surrounding an uninfamed temporal artery as a diagnostic criterion for polymyalgia rheumatica: Comment on the article by Chatelain et al. <i>Arthritis and Rheumatism</i> , 2009, 60, 2853-2854.	6.7	2
105	B lymphocytes may play a significant role in large-vessel vasculitis. <i>International Journal of Clinical Rheumatology</i> , 2012, 7, 475-477.	0.3	2
106	THU0202â€¦Prospective evaluation of aortic structural damage (aneurysm/dilatation) using a predefined screening protocol in biopsy-proven giant-cell arteritis patients during long-term follow-up. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 223.3-224.	0.9	2
107	Monogenic autoinflammatory diseases: General concepts and presentation in adult patients. <i>Medicina Clínica (English Edition)</i> , 2018, 150, 67-74.	0.2	2
108	FRI0487â€¦UTILITY OF TRABECULAR BONE SCORE(TBS) FOR FRACTURE RISK ASSESSMENT IN GLUCOCORTICOID-INDUCED OSTEOPOROSIS. , 2019, , .		2

#	ARTICLE	IF	CITATIONS
109	Polyarteritis Nodosa. , 2008, , 87-92.		2
110	Arteriovenous malformation of the brain mimicking primary central nervous system vasculitis. Scandinavian Journal of Rheumatology, 2008, 37, 481-484.	1.1	1
111	THU0222â€¦Differences in clinical presentation and outcome in patients with early versus late onset giant-cell arteritis (GCA): Analysis of 94 patients. Annals of the Rheumatic Diseases, 2013, 71, 230.2-230.	0.9	1
112	Single-Organ Genitourinary Vasculitis. Rare Diseases of the Immune System, 2021, , 241-253.	0.1	1
113	Anakinra and canakinumab for patients with R92Q-associated autoinflammatory syndrome: a multicenter observational study from the AIDA Network. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2110371.	2.7	1
114	POS0121â€¦RESPONSE OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGITIS TO MEPOLIZUMAB ACCORDING TO DISEASE MANIFESTATIONS. A SINGLE CENTRE EXPERIENCE. Annals of the Rheumatic Diseases, 2021, 80, 272.1-272.	0.9	1
115	HIV-associated vasculitis. Part II: histologic and angiographic diagnostic reconfirmation after an uncontrolled HIV infection and fatal outcome. Clinical and Experimental Rheumatology, 2019, 37 Suppl 117, 151-152.	0.8	1
116	Efficacy of canakinumab in a patient with adult-onset glucocorticoid-resistant periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis syndrome. Modern Rheumatology Case Reports, 2023, 7, 276-279.	0.7	1
117	B-cell depletion therapy in patients with refractory Wegenerâ€™s granulomatosis with head and neck manifestations. International Journal of Clinical Rheumatology, 2010, 5, 29-32.	0.3	0
118	OP0056â€¦The PTPN22/CSK Signalling Pathway is Involved in Susceptibility to Develop Giant Cell Arteritis. Annals of the Rheumatic Diseases, 2013, 72, A68.3-A69.	0.9	0
119	FRI0232â€¦Treatment with angiotensin II receptor-blockers is associated with lower relapse rate and reduced duration of treatment in patients with giant cell arteritis. Annals of the Rheumatic Diseases, 2013, 71, 392.3-393.	0.9	0
120	Authorsâ€™ response to the eLetter by Moisevet al. Annals of the Rheumatic Diseases, 2014, 73, e71-e71.	0.9	0
121	Eosinophilic granulomatosis with polyangitis (Churg-Strauss) and severe pericardial effusion. Medicina Clnica (English Edition), 2017, 148, e53.	0.2	0
122	Protocolo diagnstico de las vasculitis sistmicas. Medicina, 2017, 12, 1739-1743.	0.0	0
123	Mujer de 75 aos con arteritis de clulas gigantes y dolor torcico. Medicina, 2017, 12, 1744.e1-1744.e4.	0.0	0
124	Granulomatosis eosinoflica con poliangitis (Churg-Strauss) y derrame pericrdico grave. Medicina Clnica, 2017, 148, e53.	0.6	0
125	AB0575â€¦Retrospective survey of concomitant autoimmune diseases and autoantibodies in a cohort of patients with anca-associated vasculitis (AAV). , 2017, , .		0
126	FRI0324â€¦Small vessel vasculitis surrounding a preserved temporal artery: a diagnostic algorithm to assess clinical significance. , 2017, , .		0



#	ARTICLE	IF	CITATIONS
127	An update on isolated retinal vasculitis. <i>Minerva Oftalmologica</i> , 2017, 59, .	0.1	0
128	A very late presentation of polymyalgia rheumatica in a patient with giant cell arteritis: recurrence or casual association?. <i>Modern Rheumatology Case Reports</i> , 2019, 3, 130-133.	0.7	0
129	THU0588â€¦CLINICAL PHENOTYPES OF IGG4-RELATED DISEASE IN SPAIN. , 2019, , .		0
130	FRI0466â€¦RISK FACTORS ASSOCIATED WITH THE DEVELOPMENT OF FRACTURES IN GLUCOCORTICOID TREATED PATIENTS. THE ROLE OF HYPOGONADISM. , 2019, , .		0
131	THU0305â€¦PREVALENCE AND CLINICAL OUTCOME OF INTERSTITIAL LUNG DISEASE IN ANCA ASSOCIATED VASCULITIS. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 381.2-381.	0.9	0
132	SAT0467â€¦LOW SERUM OSTEOCALCIN LEVELS ARE ASSOCIATED WITH THE PRESENCE OF DIABETES MELLITUS IN GLUCOCORTICOID TREATED PATIENTS.. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1191.1-1191.	0.9	0
133	Occlusive vasculopathy in human immunodeficiency virus (HIV)-associated vasculitis: unusual clinical and imaging course. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 103, 185-188.	0.8	0
134	Anakinra-induced psoriasis in a patient with Schnitzler's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.8	0
135	MO241: Nets and Terminal Complement Pathway as Potential Biomarkers for Complement Overactivation Assessment in Anca-Associated Vasculitis. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.7	0